rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Maravai LifeSciences Holdings, Inc.

MRVI · Nasdaq

Health CareLife-science toolsLeadingSynthetic Biology / TechBio

MRVI stood above a rising 150-day average in 45 of the last 52 weekly readings, including each of the last 27 weeks. It is 22.1% above that average now. Life Science Tools & Research Services: 52% of its 79 stocks in an uptrend (+4 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Leading
Weeks in an uptrend
27 in a row
Industry in uptrend
52% +4 in 4 wk
Insider buys, 12 months
$1.9M
Insider sales, 12 months
$508K
Officials’ trades on record
1
Institutions holding
171 (+24)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 45 of 52 weeks.

17 Apr – 16 Oct
26%41%57%Apr 26Jun 26Jul 26Sep 26Oct 26

Life-science tools: About half its stocks are in an uptrend and the share has been climbing. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$435K$0$1.4MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

1 disclosed lines: House 1, Senate 0, executive 0; 1 people.

WhoDidAmountTraded
Daniel S. Goldman House: U.S. House ClerkNY10sold$1k–$15k10 Apr 2023filed 19 May 2023

Insiders

Buy orders, 12 months5
Sale orders, 12 months2
Buyers · sellers2 · 1
WhoDidSharesTraded
Kurt OreshackGeneral Counselsold25,000at $5.1010 Jun 2026filed 10 Jun 2026
Kurt OreshackGeneral Counselsold25,000at $5.069 Jun 2026filed 10 Jun 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders171+24 on the quarter
New · exited47 · 23
Reported value$872.3M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
GTCR LLCunchanged · filed 13 Aug 202620,150,005$125.7M00.0%
BlackRock, Inc.added · filed 7 Aug 20269,970,780$62.2M+625,512+6.7%
BRAIDWELL LPreduced · filed 14 Aug 20268,702,921$54.3M-1,537,243−15.0%
12 West Capital Management LPreduced · filed 14 Aug 20267,060,195$44.1M-200,000−2.8%
MILLENNIUM MANAGEMENT LLCadded · filed 14 Aug 20266,508,220$40.6M+4,858,730+294.6%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 20265,283,665$33.0M-166,037−3.0%
Ophir Asset Management Pty Ltdnew · filed 14 Aug 20264,826,698$30.1M+4,826,698
RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 20264,606,491$28.7M+341,802+8.0%
DEUTSCHE BANK AG\added · filed 7 Aug 20264,304,927$26.9M+3,446,672+401.6%
First Eagle Investment Management, LLCadded · filed 5 Aug 20263,671,287$22.9M+1,146,951+45.4%
31 Mar 2023 – 30 Jun 2026
133161189Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Bernd Brust Company insiderChief Executive Officer · last 8 Oct 20263 · 0
Rajesh Asarpota Company insiderChief Financial Officer · last 30 Sep 20260 · 0
Kurt Oreshack Company insiderGeneral Counsel · last 10 Jun 20261 · 3
Gregory T. Lucier Company insiderDirector · last 9 Jun 20263 · 0
Constantine S. Mihas Company insiderDirector · last 26 May 20260 · 0
John A. DeFord Company insiderDirector · last 26 May 20261 · 0
Luke Joseph Marker Company insiderDirector · last 26 May 20260 · 0
R. Andrew Eckert Company insiderDirector · last 26 May 20260 · 0
Sean Laurence Cunningham Company insiderDirector · last 26 May 20260 · 0
Susannah Gray Company insiderDirector · last 26 May 20261 · 0
Christine Dolan Company insiderOfficer · last 15 May 20260 · 0
Peter Michael Leddy Company insiderOfficer · last 15 Jul 20250 · 0

Same industry

OABI OmniAbLeading+65%
TXG 10x GenomicsLeading+60%
AVTR AvantorLeading+47%
ILMN IlluminaLeading+44%
RVTY RevvityLeading+37%
MASS 908 DevicesLeading+31%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202518.3%
Operating profit marginFY 2025 · to 31 Dec 2025-116%
Free cash flow marginFY 2025 · to 31 Dec 2025-38.1%
Return on capital employedFY 2025 · to 31 Dec 2025-29.7%
Debt to equityFY 2025 · to 31 Dec 20251.40×
Research spendFY 2025 · to 31 Dec 20259.4%
Revenue growthFY 2024 · to 31 Dec 2024275%
Share count trendFY 2024 · to 31 Dec 2024-2.6%
Cash and equivalentsFY 2025 · to 31 Dec 2025$216.9M
Free cash flowFY 2025 · to 31 Dec 2025−$70.7M

Analyst forecasts

No analyst forecasts yet.